OncoMatch/Clinical Trials/NCT05862337
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Is NCT05862337 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Anlotinib hydrochloride capsules, Penpulimab for hepatocellular carcinoma.
Treatment: Anlotinib hydrochloride capsules, Penpulimab — The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgical resection or ablation — curative
Subjects who received radical excision or ablation (Radio Frequency Ablation (RFA) or Microwave Ablation (MWA) only) within 4 to 12 weeks prior to randomization
Cannot have received: systemic chemotherapy
Previous use of ... systemic chemotherapy drugs
Cannot have received: antiangiogenic drugs
Previous use of antiangiogenic drugs
Cannot have received: PD-1 inhibitor
Previous use of ... PD-1 ... immunotherapy drugs
Cannot have received: anti-PD-L1 therapy
Previous use of ... Programmed Cell Death-Ligand 1 (PD-L1) ... immunotherapy drugs
Cannot have received: prophylactic TACE
Exception: more than 1 prophylactic TACE after surgery
Received more than 1 prophylactic Transcatheter Arterial Chemoembolization (TACE) treatment after surgery
Cannot have received: HAIC
received Hepatic Artery Infusion Chemotherapy (HAIC) therapy after surgery
Cannot have received: multiple surgical treatments
Exception: more than one surgical treatment for hepatocellular carcinoma
More than one surgical treatment for hepatocellular carcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05862337 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic chemotherapy, antiangiogenic drugs, PD-1 inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages